Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  



The FDA and drug pre-emption

If the Supreme Court upholds a broad view of pre-emption, restraining state courts from second-guessing safety balances performed at the FDA level, it will be advancing the cause of rational drug regulation, argues Tomas J. Philipson, who's a former senior economic adviser to the FDA commissioner and chairman of Project FDA at the Manhattan Institute.

Related Entries:



Isaac Gorodetski
Project Manager,
Center for Legal Policy at the
Manhattan Institute

Katherine Lazarski
Press Officer,
Manhattan Institute


Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.